Portland, OR -- (SBWIRE) -- 10/06/2017 -- Postmenopausal vaginal atrophy (PVA) refers to the reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased the elasticity of vaginal tissues. Various other factors that lead to the decrease in estrogen levels include perimenopause during breastfeeding, surgical menopause, pelvic radiation therapy, and chemotherapy. Symptoms of vaginal atrophy include redness, burning, itching, dyspareunia, and irritation. Diagnosis for PVA includes pelvic examination, vaginal smear test, vaginal activity test, blood test, and urine test.
Presence of favorable healthcare reforms, high unmet medical needs across emerging economies, and the gradual shift from systemic estrogen treatments, such as vaginal gels, and patches, to non-estrogenic therapies, drive the Postmenopausal Vaginal Atrophy Drugs Market. In addition, the rise in prevalence of postmenopausal vaginal atrophy further accelerates the market growth. However, low diagnosis rate and risk associated with the existing treatment options restrict the market. The advent of novel drugs with improved safety is expected to tap the unmet needs and provide lucrative market growth opportunities.
Exclusive Offer!!! Get Flat 20% discount on this report
Postmenopausal Vaginal Atrophy Drugs Market Key Segments:
By Therapy Type
By Drug Form
To request a sample copy of this report, Click Here
The key players operating in the global Postmenopausal Vaginal Atrophy Drugs Market include:
-Novo Nordisk A/S,
-Teva Pharmaceuticals Ltd.,
-Therapeutics MD, Inc.,
-Shionogi & Company,
-Limited, Allergan plc,
-Shionogi & Co. Ltd.